Also trades as: RX.V (TSXV) · $vol 0M
BIOYF OTC
BioSyent Inc.
1W: -2.8%
1M: +0.2%
3M: +11.4%
YTD: +23.4%
1Y: +35.0%
3Y: +100.9%
5Y: +112.0%
$11.49
-0.01 (-0.09%)
Weekly Expected Move ±6.0%
$10
$11
$11
$12
$13
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$43M
+22.8% ▲
5Y CAGR: +14.0%
Gross Profit
$32M
+15.2% ▲
5Y CAGR: +13.0%
Operating Income
$11M
+29.1% ▲
5Y CAGR: +17.6%
Net Income
$9M
+23.9% ▲
5Y CAGR: +18.9%
EPS (Diluted)
$0.78
+21.9% ▲
5Y CAGR: +21.9%
EBITDA
$12M
+16.5% ▲
5Y CAGR: +17.0%
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $29M | $28M | $32M | $35M | $43M |
| YoY Growth | +28.1% | -2.4% | +13.1% | +10.9% | +22.8% |
| Cost of Revenue | $6M | $5M | $6M | $7M | $11M |
| Gross Profit | $23M | $23M | $26M | $28M | $32M |
| Gross Margin | 79.1% | 81.9% | 81.0% | 79.5% | 74.6% |
| R&D Expenses | $277K | $218K | $83K | $171K | $341K |
| SG&A Expenses | $14M | $15M | $18M | $18M | $20M |
| Operating Expenses | $14M | $16M | $18M | $19M | $21M |
| Operating Income | $8M | $7M | $7M | $9M | $11M |
| Operating Margin | 28.6% | 25.0% | 23.7% | 25.0% | 26.3% |
| Interest Expense | $85K | $77K | $68K | $59K | $49K |
| Income Before Tax | $8M | $7M | $9M | $10M | $12M |
| Tax Expense | $2M | $2M | $2M | $3M | $3M |
| Net Income | $6M | $5M | $6M | $7M | $9M |
| Net Margin | 21.9% | 19.5% | 20.4% | 20.8% | 20.9% |
| EPS (Diluted) | $0.49 | $0.44 | $0.53 | $0.64 | $0.78 |
| EBITDA | $9M | $7M | $8M | $10M | $12M |
| Shares Outstanding | 13M | 13M | 12M | 11M | 12M |